Key statistics
On Tuesday, InnoCare Pharma Ltd (688428:SHH) closed at 25.06, -26.34% below its 52-week high of 34.02, set on Aug 18, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 24.38 |
|---|---|
| High | 25.47 |
| Low | 24.00 |
| Bid | 25.05 |
| Offer | 25.06 |
| Previous close | 24.30 |
| Average volume | 15.34m |
|---|---|
| Shares outstanding | 1.76bn |
| Free float | 1.46bn |
| P/E (TTM) | -- |
| Market cap | 23.78bn CNY |
| EPS (TTM) | -0.1508 CNY |
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Announcements
- InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
- Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
- InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
- InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
- InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
- InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
- Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
- Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
- InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
- InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China
More ▼
